Stavudine


Generic Medicine Info
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to stavudine. Lactation.
Special Precautions
Patient w/ hepatomegaly, hepatitis or other risk factors for liver disease (esp obese women); pre-existing bone marrow suppression; history of peripheral neuropathy; history of or risk factors for pancreatitis. Renal or hepatic impairment. Pregnancy. Patient Counselling This drug may cause dizziness and/or somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Monitor LFTs, renal function tests, viral load, CD4 count.
Adverse Reactions
Peripheral neuropathy, abdominal pain, nausea, drowsiness, diarrhoea, dyspepsia, fatigue, dizziness, headache, abnormal dreams, depression, insomnia, pruritus, rash, immune reconstitution syndrome, lipodystrophy (including central obesity, facial and peripheral wasting, breast enlargement, cushingoid appearance, dorsocervical fat enlargement), metabolic abnormalities (e.g. hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia, hyperlactataemia), mitochondrial dysfunction (manifesting as abnormal behaviour, convulsions, anaemia, hyperlipasaemia, hypertonia, neutropenia), myalgia, myositis, elevated creatine phosphokinase, osteonecrosis. Rarely, rhabdomyolysis.
Potentially Fatal: Lactic acidosis associated w/ severe hepatomegaly and steatosis. Rarely, hepatitis, hepatic failure, pancreatitis.
Drug Interactions
Increased risk of pancreatitis, peripheral neuropathy and hepatotoxicity in combination w/ didanosine and hydroxycarbamide. Risk of hepatic decompensation w/ interferon and ribavirin. Risk of peripheral neuropathy w/ isoniazid. Zidovudine may decrease the phosphorylation of stavudine to its active triphosphate form. Doxorubicin and ribavirin may inhibit stavudine activation.
CIMS Class
Antivirals
ATC Classification
J05AF04 - stavudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on stavudine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in